(ENTA) Enanta Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ENTA) Enanta Pharmaceuticals, Inc. Complete Analysis Pack
See the Bigger Picture
This Enanta Pharmaceuticals, Inc. BCG Matrix is a company-specific strategic analysis that helps you see how its products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the report content, so you can review the format and quality before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
No owned commercial brand
Enanta Pharmaceuticals, Inc. had no internally marketed drug at year-end 2025, so it had no true Star asset in BCG terms. The company stayed a development-stage biotech, with no owned commercial brand to drive revenue scale.
Its 2025 story was still pipeline-first, not market-share-led, which is why this box stays empty in the Stars quadrant.
No direct product sales
Enanta Pharmaceuticals, Inc. had no direct product sales, so this Star box stays empty. Revenue came from collaboration and royalty economics, not from an Enanta-branded launch with a high market share. That matters because Star businesses usually need strong sales growth plus clear commercial control, and Enanta did not have that model.
No high-growth market leader
Enanta Pharmaceuticals, Inc. did not disclose a company-owned product leading a fast-growing end market, so it lacks a Star profile. Its marketed exposure came mainly from collaboration and royalty income, not from a sales force-led product launch. Without a clear in-house growth engine, the BCG "Star" bucket does not fit.
R and D only core
Enanta Pharmaceuticals, Inc.’s core is discovery and clinical development, so the "R and D only core" Star is a pipeline story, not a cash engine. Clinical-stage assets burn cash before they sell; in FY2025, that means the segment is still funding trials and data readouts rather than producing durable operating profit.
- Discovery-led, not sales-led
- Clinical assets consume cash
- Star status is strategic, not mature
Star slot vacant
At the end of 2025, Enanta Pharmaceuticals, Inc. had 0 internal "Star" assets: nothing combined high share with high growth. Its value still came from royalty income and pipeline optionality, not a market-leading owned product, so the BCG matrix had a vacant Star slot.
0 internal Stars at year-end 2025
Value tied to royalties and pipeline bets
No owned asset with high share and growth
Enanta Has No Star Assets in FY2025
Enanta Pharmaceuticals, Inc. had no owned commercial drug in FY2025, so it had 0 Star assets in BCG terms. Its value still came from collaboration and royalty income, while the pipeline stayed in R and D mode, not a high-share growth engine. That makes the Stars box empty at year-end 2025.
| Metric | FY2025 |
|---|---|
| Owned commercial products | 0 |
| Star assets | 0 |
What is included in the product
Detailed Word Document
Enanta’s BCG Matrix maps its virology pipeline and royalties into Stars, Cash Cows, Question Marks, and Dogs for capital allocation.
Editable Excel File
Quick BCG snapshot of Enanta Pharmaceuticals, Inc. to spotlight growth bets and trim portfolio noise.
Reference Sources
Provides a traceable source trail for Enanta Pharmaceuticals, Inc. that strengthens credibility and speeds smarter decisions.
Cash Cows
AbbVie HCV royalties
AbbVie HCV royalties were Enanta Pharmaceuticals, Inc.'s main recurring cash engine. In FY2025, this cash stream still fit the Cash Cow profile: low capital needs, steady licensing income, and no heavy reinvestment. As AbbVie’s hepatitis C franchise kept maturing, the royalty pool stayed valuable but slower-growth.
Mavyret royalty stream
Mavyret is AbbVie’s glecaprevir/pibrentasvir HCV franchise, and Enanta still gets royalty value from the protease inhibitor side. The market is mature, but the cash stream stays meaningful because Mavyret was a multibillion-dollar product at peak and still helps fund Enanta’s R&D. In BCG terms, this is a Cash Cow: low growth, steady cash.
Glecaprevir legacy value
Glecaprevir is Enanta Pharmaceuticals, Inc.'s best-known collaboration asset, embedded in AbbVie’s 8-week Mavyret regimen, which has shown cure rates above 95% in HCV. That makes it a classic Cash Cow: the product is mature, already commercial, and needs little new capital. The legacy royalty stream still matters, but growth is limited as the HCV market keeps shrinking.
Low-support revenue base
Enanta Pharmaceuticals, Inc.'s royalty revenue is a low-support cash source: it needs far less promotion than a launch drug, so selling costs stay light and operating drag stays lower. That matters in a model where cash can be redirected to R and D and corporate overhead instead of commercialization spend. In BCG terms, this is classic "cash cow" behavior: steady inflow, modest reinvestment, and strong internal funding power.
- Low promotion spend
- Lower operating drag
- Funds R and D
- Covers overhead needs
Mature hepatitis C franchise
Hepatitis C is a mature market, not a new-growth story, and AbbVie’s MAVYRET has been on the market since 2017. Enanta’s value here comes from royalty economics on an established franchise, so this fits Cash Cow logic: steady cash, low reinvestment, and limited upside. HCV cure rates are above 95% with modern DAAs, which caps fresh growth.
- 2017 launch, mature asset
- Royalty-led, not launch-led
- High cure rates limit growth
Enanta’s MAVYRET Royalties Remain a Stable Cash Cow
Enanta Pharmaceuticals, Inc.’s Cash Cow is its AbbVie HCV royalty stream from glecaprevir in MAVYRET. The asset is mature, low capex, and still funds R&D, but growth is limited as hepatitis C cures exceed 95% and the market keeps shrinking.
| Metric | FY2025 | Signal |
|---|---|---|
| HCV royalties | Recurring | Cash Cow |
| MAVYRET launch | 2017 | Mature |
What You See Is What You Get
Enanta Pharmaceuticals, Inc. Reference Sources
The Enanta Pharmaceuticals, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No demo pages or placeholders—just the full, polished report ready for your use. Once purchased, the file is instantly available for download, editing, or presentation.
Dogs
No material in-house dog
Enanta Pharmaceuticals, Inc. had no material in-house Dog franchise: it was mainly a development platform and royalty recipient, not a big standalone commercial brand with weak economics. That means there was no obvious low-growth, low-share product line to sell or shrink. In FY2025, its value still came more from pipeline and partner royalties than from a legacy Dog business.
Legacy HCV chemistry
Enanta Pharmaceuticals, Inc.'s legacy HCV chemistry is now a historical asset set, not a growth engine. The old hepatitis C programs have far less market weight than the Mavyret royalty stream, so in BCG terms they sit near the Dog corner: low growth and weak strategic pull.
That fits Enanta Pharmaceuticals, Inc.'s current mix, where value is tied to residual HCV economics rather than new chemistry from this block. As the HCV market keeps shrinking, these assets look more like harvest-and-manage positions than reinvestment candidates.
Paritaprevir-era asset base
Paritaprevir sits in AbbVie’s older HCV era, anchored by Viekira Pak, which won U.S. approval in 2014. By 2025, that generation had little new demand left as newer direct-acting antivirals took share. That makes it a classic Dog: low growth, low strategic weight, and limited capital need.
Non-core historical programs
Enanta Pharmaceuticals, Inc.'s non-core historical programs no longer drive meaningful revenue, so they fit the Dog bucket. Their value is mostly sunk R and D, while management time still gets tied up; Enanta Pharmaceuticals, Inc. posted a net loss in fiscal 2025, which shows how little these legacy assets help current earnings.
- Low current revenue
- High sunk R and D
- Management distraction risk
Weakest-value items
Enanta Pharmaceuticals, Inc.'s weakest-value items were the assets with no commercial traction and no clear path to scale, so they fit the Dogs bucket. The portfolio was still dominated by one royalty stream, while the leftover programs were not value drivers and did not offset the risk of a thin base.
In FY2025, Enanta reported about $61 million in total revenue, almost all from royalties, while R&D stayed the main cash use, showing how little weak assets added to the top line. That makes the non-core programs look more like optional bets than real businesses.
- No current sales traction
- No clear growth path
- Not material to revenue
- Failed to drive portfolio value
Enanta’s Legacy HCV Dogs: Harvest-Only Assets in FY2025
Enanta Pharmaceuticals, Inc.’s Dogs are the legacy HCV assets: low growth, no new demand, and little strategic pull in FY2025. Their value is mostly sunk R&D, while revenue was about $61 million and came mainly from royalties, not these weak programs. They look like harvest-only assets, not reinvestment candidates.
| Item | FY2025 | BCG fit |
|---|---|---|
| Legacy HCV assets | Low demand | Dog |
| Total revenue | About $61M | Royalties led |
Question Marks
Zelicapavir RSV
Zelicapavir is Enanta Pharmaceuticals, Inc.'s RSV antiviral program, and it fits BCG "Question Marks" because it is still clinical-stage, so current market share is near zero. RSV is a big unmet need: the CDC estimates about 177,000 adult hospitalizations and 14,000 deaths in the U.S. each year. If Zelicapavir can prove strong antiviral benefit in Phase 2/3, it could grow fast.
EDP-323 hMPV
EDP-323 targets human metapneumovirus, which has no approved antiviral in the U.S., so Enanta’s current BCG share is still low. hMPV is estimated to cause 2% to 10% of respiratory infections and can be severe in infants, older adults, and immunocompromised patients. As a clinical-stage asset, EDP-323 is a Question Mark: high upside if data are strong, but no revenue yet.
EDP-235 SARS-CoV-2
EDP-235 is Enanta Pharmaceuticals, Inc.'s SARS-CoV-2 antiviral program, and it fits the Question Mark box because it is still development-stage. The COVID-19 treatment market is still active, but it is crowded, with multiple approved antivirals already in use. That makes the asset high-upside but also high-risk, since Enanta must prove clear clinical and commercial edge.
EDP-514 HBV
EDP-514 is Enanta Pharmaceuticals, Inc.'s hepatitis B virus program, and HBV still affects about 254 million people worldwide, with roughly 1.2 million new infections each year. That keeps the market large, but EDP-514's current share is still tiny because it is not a commercial product yet. If the asset proves safe and active, it could move from a pure question mark toward a future growth driver.
- HBV: ~254 million chronic cases
- ~1.2 million new infections yearly
- High unmet need, limited current share
Early antiviral pipeline
Enanta Pharmaceuticals, Inc. keeps its early antiviral pipeline in the Question Marks bucket because these small-molecule programs target unmet-need markets but still need heavy R&D spend before any sales show up. That means cash burn stays high now, while the upside is real if a candidate clears clinical risk and gains share. If one or two assets reach approval, this group can shift toward future Stars.
High R&D, no near-term revenue
Built for unmet-need antiviral niches
Success could re-rate into Stars
Enanta’s Antivirals: High-Risk Question Marks With Big Upside
Enanta Pharmaceuticals, Inc.'s Question Marks are early antiviral programs with low current share but big upside if data land: Zelicapavir, EDP-323, EDP-235, and EDP-514. They target RSV, hMPV, COVID-19, and HBV, all large need areas, but each is still clinical-stage and not yet a revenue driver. R&D spend stays high now, but a win could lift one or more into future Stars.
| Program | Status | Market note |
|---|---|---|
| Zelicapavir | Clinical-stage | RSV: 177,000 U.S. adult hospitalizations; 14,000 deaths |
| EDP-323 | Clinical-stage | hMPV: 2% to 10% of respiratory infections |
| EDP-514 | Clinical-stage | HBV: 254 million chronic cases |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.